Plain-English translation of NCT06696794 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether mitomycin C—a medication instilled directly into the bladder—combined with a specialized surgical technique can help prevent bladder cancer from returning in patients with high-risk disease. Researchers want to know if this medication given before surgery improves outcomes and what side effects patients experience compared to a placebo.
High-risk bladder cancer has a significant chance of coming back even after standard surgery. This trial exists to see whether giving this medication before surgery can reduce that recurrence risk and improve long-term survival for patients.
You likely qualify if…
You likely don't qualify if…
You will receive either the medication or a placebo through the bladder twice—once 1 day before surgery and again 4 hours before surgery. You will then undergo the specialized surgical procedure. After that, you'll visit the clinic every 8 weeks for checkups and imaging to monitor whether the cancer returns or progresses. The trial will track your health and any side effects throughout this follow-up period.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China